title: Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population.
abstract: OBJECTIVE
  To record in real life the appreciation of elderly patients, their caregivers and physicians of a once daily formulation of prolonged release of galantamine in the treatment of mild to moderate Alzheimer's disease.
  
  
  METHODS
  A prospective, multicenter, observational study was conducted in 128 elderly patients, treated for 6 months with galantamine, donepezil or rivastigmine.
  
  
  RESULTS
  Of the patients treated with galantamine, 82 of the 97 (84.5%) were continuing their treatment after 6 months. These patients reported their condition as improved in 49%, unchanged in 47% and worsened in 4%. Caregivers rated global evaluation as 37% better, 41% unchanged and 22% worse. Physicians rated global clinical impression of change as 46% better, 34% unchanged and 20% worse. Measurements of cognition and behavior remained stable. The appreciation of physicians and caregivers corresponded well (P<0.001). The incidence of serious side-effects possibly related to galantamine was 9.3%, which was not different from that in patients treated with other cholinesterase inhibitors.
  
  
  CONCLUSIONS
  In a real life setting, galantamine once daily is safe and is favorably appreciated by patients, their caregivers and physicians.
authors.affiliation: Geriatrics Department, Universitair Ziekenhuis Brussel, Brussels, Belgium.
authors.forename: Katrien
authors.initials: K
authors.lastname: Van Puyvelde
authors.forename: Tony
authors.initials: T
authors.lastname: Mets
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D017028:Caregivers; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D003071:Cognition; D003692:Delayed-Action Preparations; D000077265:Donepezil; D005260:Female; D005702:Galantamine / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008297:Male; D017060:Patient Satisfaction; D048448:Phenylcarbamates / Q000627:therapeutic use; D010880:Piperidines / Q000627:therapeutic use; D000068836:Rivastigmine; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D003692:Delayed-Action Preparations; D007189:Indans; D048448:Phenylcarbamates; D010880:Piperidines; D005702:Galantamine; D000077265:Donepezil; D000068836:Rivastigmine